Arch. Dis. Child

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strunk, T
Right arrow Articles by Schultz, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strunk, T
Right arrow Articles by Schultz, C
Archives of Disease in Childhood Fetal and Neonatal Edition 2004;89:F364
© 2004 Archives of Disease in Childhood Fetal and Neonatal Edition


HYPOTHESIS

Does erythropoietin protect the preterm brain?

T Strunk, C Härtel, C Schultz

Department of Paediatrics, University of Lübeck Medical School, Lübeck, Germany

Correspondence to:
Correspondence to:
Dr Schultz
University Hospital Schleswig-Holstein, Campus Lübeck, Department of Paediatrics, Ratzeburger Allee 160, 23538 Lübeck, Germany; schultz{at}paedia.ukl.mu-luebeck.de


ABSTRACT
There is a high incidence of hypoxic-ischaemic brain injury and intraventricular haemorrhage in newborn infants, particularly those born preterm. Many die during the newborn period or suffer permanent neurodevelopmental handicaps. Hypoxic brain injury develops over several hours and could potentially be influenced by intervention. At present, no drug exists that effectively prevents infant brain injury or ameliorates detrimental neurodevelopmental effects. The hypothesis is put forward that systemic administration of recombinant human erythropoietin positively affects the neurodevelopmental outcome of high risk preterm infants affected by brain injury. A multicentre, randomised, placebo controlled study is proposed to prospectively test this hypothesis.


Abbreviations: Epo, erythropoietin; EpoR, erythropoietin receptor

Keywords: erythropoietin; neuroprotection; preterm; brain




This article has been cited by other articles:


Home page
Am. J. Neuroradiol.Home page
N. G. Anderson, I. Laurent, N. Cook, L. Woodward, and T. E. Inder
Growth Rate of Corpus Callosum in Very Premature Infants
AJNR Am. J. Neuroradiol., November 1, 2005; 26(10): 2685 - 2690.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health